Patient who is pregnant and/or breastfeeding
Pregnant or lactating women
Woman who are pregnant or breastfeeding
TREATMENT: Pregnant
Pregnant or breastfeeding
Pregnant women are eligible to participate in this study
Females who are pregnant or breastfeeding are ineligible
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
Breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
Pregnant women are excluded from this study
TUMOR BIOPSY SEQUENCING: Women who are pregnant or breastfeeding
TREATMENT: Breastfeeding should be discontinued while the patient is on this trial and for 30 days following last dose of study drug
TREATMENT: Women who are pregnant or breastfeeding
Women who are pregnant or breastfeeding
Pregnant and breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding women
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
Pregnant women are excluded; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
If pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-3475
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with dabrafenib/trametinib
Pregnant women and women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study
Not pregnant or nursing, with negative serum pregnancy test; pregnant women are excluded from this study; breastfeeding should be discontinued; timeline: within 3 weeks prior to enrollment
Pregnant women
Pregnant women and women who are breastfeeding are excluded from this study
